Evidence map›Paper›PMID 41827314›Full record

ArticleJournal of clinical medicine2026

Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Şahin Bedir, Tanju Kapagan, Burçin Çakan Demirel, Merve Tokocin, Çiğdem Yıldırım, Semra Taş, Yakup Bozkaya, Abdilkerim Oyman, Nilufer Bulut, Gökmen Umut Erdem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Şahin BedirDepartment of Medical Oncology, Faculty of Medicine, Istinye University, Gaziosmanpaşa Hospital, Istanbul 34250, Turkey.ORCID 0000-0002-5797-0804
Tanju KapaganDepartment of Medical Oncology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul 34480, Turkey.ORCID 0000-0001-9381-1934
Burçin Çakan DemirelDepartment of Medical Oncology, Istanbul Medipol University, Medipol Mega University Hospital, Istanbul 34214, Turkey.ORCID 0000-0003-0734-0692
Merve TokocinDepartment of General Surgery, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul 34100, Turkey.ORCID 0000-0001-8040-300X
Çiğdem YıldırımDepartment of Medical Oncology, University of Health Sciences, Samatya Training and Research Hospital, Istanbul 34098, Turkey.
Semra TaşDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University Hospital, Denizli 20360, Turkey.
Yakup BozkayaDepartment of Medical Oncology, Faculty of Medicine, Istinye University, Gaziosmanpaşa Hospital, Istanbul 34250, Turkey.
Abdilkerim OymanDepartment of Medical Oncology, Faculty of Medicine, Istinye University, Gaziosmanpaşa Hospital, Istanbul 34250, Turkey.
Nilufer BulutDepartment of Medical Oncology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul 34480, Turkey.ORCID 0000-0002-2406-1946
Gökmen Umut ErdemDepartment of Medical Oncology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul 34480, Turkey.ORCID 0000-0002-3375-9465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerCDK 4/6 inhibitorsendocrine therapyHER2-lowHER2-zero

Identifiers

PMID41827314
PMCPMC12986363

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.